LOGIN  |  REGISTER

Mettler-Toledo to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 20, 2024 | Last Trade: US$1,209.12 34.40 2.93

COLUMBUS, Ohio / Dec 20, 2024 / Business Wire / Mettler-Toledo International Inc. (NYSE: MTD) today announced it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14, 2025 at 3:45 p.m. Pacific Time. A live webcast of the presentation will be available on the Company’s investor relations website at investors.mt.com.

METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.

Recursion

Stock Quote

Last Trade: US$1,209.12
Daily Change: 34.40 2.93
Daily Volume: 89,461
Market Cap: US$25.510B

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page